FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/04/2022
Voltar para busca
Dado oficial do USPTO
PRÉNUMBRA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
24
Atualização mais recente
18/04/2022
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
11/08/2020
Data de registro
05/10/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/10/2021
Última transação
18/04/2022
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
WELLS, KELLEY
Unidade examinadora
M90
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Clinuvel (UK) Ltd
Representantes
Mark M. Friedman Dr. Mark Friedman Ltd
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceuticals for the prevention and treatment of autoimmuneinflammatory and skin diseases or disordersfor the treatment of viralmetabolicendocrinemusculoskeletalophthalmiccardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamicvasoactive and anti-oncotic pharmaceuticals; Pharmaceutical drugs for the prevention and treatment of autoimmuneinflammatory and skin diseases or disordersfor the treatment of viralmetabolicendocrinemusculoskeletalophthalmiccardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamicvasoactive and anti-oncotic pharmaceutical drugs; Pharmaceutical preparations for the prevention and treatment of autoimmuneinflammatory and skin diseases or disordersfor the treatment of viralmetabolicendocrinemusculoskeletalophthalmiccardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disordersfor the treatment of vascular anomalies and oedema and for the prevention and treatment of genetic diseases and disorders; hemodynamicvasoactive and anti-oncotic pharmaceutical preparations; Pharmaceuticals used for cerebrovascular accidents in the nature of strokes; Cardiovascular drug preparations; Cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; Cardiovascular medicinal agents for medical purposes; Cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (CHF); Pharmaceutical preparationspreferably based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide for use in treating skin and skin relating conditions and disorders; Medicated sun tanning preparations for pharmaceutical purposespreferably based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; Pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; Medicated dermatological preparations; Dermatological pharmaceutical substances; Dermatological pharmaceutical productspreparations for treating or preventing skin disorders; Medicinal creams for the protection of the skin; Medicated skin care creams for medical use for treating or preventing skin disorders; Medicated skin care preparations for medical use; Medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; Chemical and biological preparationssubstancesreagents and compounds for the delivery and storage of a wide range of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (MSH)in particular afamelanotide; Afamelanotide hormone in aqueous and gel formulations
Publicações
Histórico de despachos e eventos da marca no USPTO.
24 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
24/03/2022
FIMP
FINAL DISPOSITION PROCESSED
24/03/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
05/10/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/07/2021
PUBO
PUBLISHED FOR OPPOSITION
20/07/2021
GPNX
NOTIFICATION PROCESSED BY IB
19/07/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
30/06/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
30/06/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/06/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
17/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
16/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
16/06/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
16/06/2021
RFNT
REFUSAL PROCESSED BY IB
11/01/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
21/12/2020
RFRR
REFUSAL PROCESSED BY MPU
21/12/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/12/2020
CNRT
NON-FINAL ACTION WRITTEN
13/12/2020
DOCK
ASSIGNED TO EXAMINER
06/12/2020
MAFR
APPLICATION FILING RECEIPT MAILED
23/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
19/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
15/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace PRÉNUMBRA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.